Clinical utility of companion diagnostic biomarker results below the limit of detection in comprehensive genomic profiling of patients with advanced non-small cell lung cancer

Most patients who receive a targeted therapy matched to a companion diagnostic biomarker detected and reported below LoD demonstrate clinical benefit from that therapy. This clinical observation suggests actionable variants should continue to be reported when detected with FMI CGP tests.